Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes

Nat Genet. 2026 Jun 22. doi: 10.1038/s41588-026-02646-3. Online ahead of print.ABSTRACTMost genetic variants associated with complex heritability phenotypes lie in non-coding regions and are thought to influence disease risk by regulating gene expression. However, most transcriptome-wide association

F Fabiana Rossi

Machine-intelligent multimodal algebot for intracavitary chemotherapy

Nat Nanotechnol. 2026 Jun 22. doi: 10.1038/s41565-026-02195-0. Online ahead of print.ABSTRACTIntracavitary drug instillation is a crucial therapeutic strategy for treating bladder cancer. However, current methods are limited in efficacy due to insufficient tumour targeting and drug penetration acros

L Lin Lin

The burden of cardiovascular disease in prostate cancer: prevalence, pathophysiology, and implications for integrated care

Support Care Cancer. 2026 Jun 23;34(7):680. doi: 10.1007/s00520-026-10913-6.ABSTRACTCardiovascular disease (CVD) and cancer are the two leading health issues in the world, with CVD being the leading cause of death in all age groups and cancer, particularly prostate cancer (PCa), emerging as a signif

I Ikponmwosa Jude Ogieuhi

In Response to "Quantifying the population burden of hypertension: methodological considerations on the PAF analysis of the DeSC cohort"

No abstractHypertens Res. 2026 Jun 23. doi: 10.1038/s41440-026-02705-6. Online ahead of print.NO ABSTRACTPMID:42332085 | DOI:10.1038/s41440-026-02705-6

M Masachika Nishikawa

An interpretable combinatorial data-mining framework for predicting new-onset hypertension in the general population

Hypertens Res. 2026 Jun 22. doi: 10.1038/s41440-026-02715-4. Online ahead of print.ABSTRACTWe previously established an interpretable combinatorial data-mining framework to identify combinations of clinical factors predictive of heart failure. Because hypertension (HT) is a major contributor to hear

Y Yohei Miyashita

LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis

Int J Obes (Lond). 2026 Jun 22. doi: 10.1038/s41366-026-02126-y. Online ahead of print.ABSTRACTBACKGROUND/OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally and can progress to metabolic dysfunction-associated steatohepat

Q Qiurong Zhao

Fulminant Clostridioides difficile pseudomembranous colitis requiring subtotal colectomy after pancreaticoduodenectomy: A case report and mini-review

Ann Hepatobiliary Pancreat Surg. 2026 Jun 23. doi: 10.14701/ahbps.26-057. Online ahead of print.ABSTRACTPseudomembranous colitis due to Clostridioides difficile infection (CDI) is a serious complication of antibiotic therapy and hospitalization that can progress to toxic megacolon, necessitating eme

B Beata Hemmelová

Adult Burn Survivors Face Elevated Long-Term Risk of Major Adverse Cardiovascular Events, Venous Thromboembolism, and Mortality: A Real-World Analysis

Adv Wound Care (New Rochelle). 2026 Jun 22:21621918261462931. doi: 10.1177/21621918261462931. Online ahead of print.ABSTRACTOBJECTIVE: Burn injuries affect millions globally, with increasing survival rates due to advances in acute care. However, long-term cardiovascular outcomes including major adve

Y Yu-Hsiang Lin

Glucagon-Like Peptide-1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

Diabetes Obes Metab. 2026 Jun 22. doi: 10.1111/dom.71023. Online ahead of print.ABSTRACTAIMS: Treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. While glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT-2) inh

G Gregor A Maier

Effects of Weight-Loss Interventions on Kidney, Cardiometabolic and Anthropometric Outcomes in Adults With CKD and Overweight or Obesity: A Systematic Review and Meta-Analysis

Diabetes Obes Metab. 2026 Jun 22. doi: 10.1111/dom.70997. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: Obesity and chronic kidney disease (CKD) are highly prevalent conditions with substantial public health impacts; their co-existence is common and associated with an aggravated risk for advers

A Anastasia Stamatiou

Lipoprotein(a) and coronary inflammation: Joint predictors of residual risk in post-percutaneous coronary intervention coronary artery disease

J Clin Lipidol. 2026 Jun 6:S1933-2874(26)00381-8. doi: 10.1016/j.jacl.2026.05.242. Online ahead of print.ABSTRACTBACKGROUND: The interaction of elevated lipoprotein(a) [Lp(a)] with local coronary inflammation remains unclear.OBJECTIVE: We investigated whether pericoronary inflammation modulates Lp(a

Z Zixiang Ye

Metabolic dysfunction-associated fatty liver disease and cardiac remodeling in non-ischemic dilated cardiomyopathy

Nutr Metab Cardiovasc Dis. 2026 Apr 12:104752. doi: 10.1016/j.numecd.2026.104752. Online ahead of print.ABSTRACTBACKGROUND AND AIM: Metabolic dysfunction-associated fatty liver disease (MAFLD) represents systemic metabolic dysfunction and is significantly associated with cardiovascular disease. Howe

J Jinjie Wang

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease

Rev Med Interne. 2026 Jun 22:S0248-8663(26)00630-2. doi: 10.1016/j.revmed.2026.06.005. Online ahead of print.ABSTRACTSystemic sclerosis (SSc) is a rare systemic disease characterised by progressive fibrosis, vasculopathy, and immune dysregulation, resulting in multiorgan damage. Independently of pul

R Raffaele Barile

Pitfalls of therapies targeting the nitric oxide signaling pathway in heart failure with preserved ejection fraction

J Cardiovasc Pharmacol. 2026 Jun 22. doi: 10.1097/FJC.0000000000001844. Online ahead of print.ABSTRACTOver 30 million individuals globally are afflicted with heart failure with preserved ejection fraction (HFpEF). Despite this substantial figure, treatment options for HFpEF remain limited. This is l

S Skylar A Loeb

Coronary microvascular dysfunction in menopausal women

Heart. 2026 Jun 22:heartjnl-2026-328124. doi: 10.1136/heartjnl-2026-328124. Online ahead of print.ABSTRACTCardiovascular disease (CVD) accounts for a third of all deaths, making it the leading cause of mortality globally. Coronary microvascular dysfunction (CMD) has emerged as a prominent condition

D Denin Mathew

Type 2 diabetes and the risk of hospitalisation and mortality from seasonal influenza: an observational register-based study in Sweden

BMJ Open. 2026 Jun 22;16(6):e106480. doi: 10.1136/bmjopen-2025-106480.ABSTRACTOBJECTIVES: To compare influenza-related hospitalisation, mortality and effects of background factors in adults with type 2 diabetes (T2D) and age-matched and sex-matched controls. To explore associations between clinical

E Elin Allansson Kjölhede

Association of ischaemic stroke/TIA with subsequent oral anticoagulant adherence in patients with atrial fibrillation: a scoping review

BMJ Open. 2026 Jun 22;16(6):e112736. doi: 10.1136/bmjopen-2025-112736.ABSTRACTOBJECTIVES: This study aimed to investigate the association and potential causal relationship between ischaemic stroke/transient ischaemic attack (TIA) and oral anticoagulant (OAC) adherence using Bradford Hill's criteria

A Aashiq Ahamed Shukkoor

Treatment and control of low-density lipoprotein for primary prevention in patients in Wales with and without depression: a study of whole-population electronic health records

Open Heart. 2026 Jun 22;13(1):e003800. doi: 10.1136/openhrt-2025-003800.ABSTRACTAIM: This study investigated the influence of depression status on lipid lowering therapy (LLT) prescribing and achievement of guideline targets for low density lipoprotein cholesterol (LDL-C) levels in patients after fi

C Carla White

Equitable lipid optimisation through a data-driven, pharmacist-led secondary prevention pathway

Open Heart. 2026 Jun 22;13(1):e004089. doi: 10.1136/openhrt-2026-004089.ABSTRACTBACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in the UK, with raised cholesterol contributing to 25%-28% of ASCVD deaths. Despite well-established guidelines, ch

J Joshua Xu

Early versus delayed EKOS thrombolysis in intermediate-high risk pulmonary embolism: a retrospective multicentre analysis

Open Heart. 2026 Jun 22;13(1):e004271. doi: 10.1136/openhrt-2026-004271.ABSTRACTBACKGROUND: Ultrasound-assisted catheter-directed thrombolysis using the EkoSonic Endovascular System (EKOS) is an established treatment for intermediate high-risk pulmonary embolism (IHR-PE). However, the optimal timing

J Julia Schulten-Baumer

Incorporation of dose-rate effects into the BIANCA biophysical model and application for space radiation risk assessment

Life Sci Space Res (Amst). 2026 Jul;51:3-10. doi: 10.1016/j.lssr.2025.09.002. Epub 2025 Sep 9.ABSTRACTExposure to space radiation represents a critical issue for astronauts' health, since it can lead to different types of effects including cancer, cataract, skin damage, damage to blood forming organ

E E I Canay

Transcarotid UNICORN Procedure to Facilitate Valve-in-Valve TAVR

No abstractJACC Cardiovasc Interv. 2026 Jun 22;19(12):1700-1702. doi: 10.1016/j.jcin.2026.04.038.NO ABSTRACTPMID:42331424 | DOI:10.1016/j.jcin.2026.04.038

F Firas Barrow

Modification of Calcified Native and Surgical Bioprosthetic Aortic Valves: Lessons From the Bench

JACC Cardiovasc Interv. 2026 Jun 22;19(12):1650-1663. doi: 10.1016/j.jcin.2026.05.005.ABSTRACTBACKGROUND: Leaflet modification (LM) techniques, including electrosurgical and mechanical BASILICA (bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstr

L Lucca Loretz

Leaflet Modification to Mitigate Coronary Obstruction Risk During TAVR: Results From the LOFTER-TAVR Registry

JACC Cardiovasc Interv. 2026 Jun 22;19(12):1639-1649. doi: 10.1016/j.jcin.2026.05.011.ABSTRACTBACKGROUND: Coronary obstruction (CO) is a rare but life-threatening complication of transcatheter aortic valve replacement (TAVR). Leaflet modification techniques have been developed to mitigate this risk;

G Giovanni Occhipinti